Related Experiment Video
Updated: Dec 25, 2025
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.5K
Recent advances in understanding chemotherapy-induced peripheral neuropathy.
Richard Gordon-Williams1, Paul Farquhar-Smith1
1Department of Pain Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
F1000Research
|March 24, 2020
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) causes pain and reduces quality of life. Despite scientific advances, effective preventative measures and treatments for CIPN remain limited, necessitating further research.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) significantly impacts cancer patients' quality of life.
- Despite pre-clinical advancements, translation to clinical preventative measures and treatments for CIPN is lacking.
Purpose of the Study:
- To provide an updated review of pre-clinical science related to CIPN.
- To summarize current preventative measures, assessment methods, and treatment options for CIPN.
Main Methods:
- Literature review of pre-clinical studies on CIPN.
- Analysis of current clinical guidelines and research on CIPN prevention and treatment.
Main Results:
- Review highlights progress in understanding CIPN mechanisms.
- Identifies a gap between pre-clinical findings and clinical application for CIPN.
- Summarizes existing, though often limited, strategies for CIPN management.
Conclusions:
- Further research is crucial to translate pre-clinical findings into effective clinical interventions for CIPN.
- Improved strategies for CIPN prevention and treatment are needed to enhance cancer patient outcomes.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
464
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
464
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
733
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
733
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
527
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
527
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
605
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
605
01:26Peripheral Artery Disease IV: Nursing Management
248
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
248
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K